Clinical Trial Update: RNActive®-Derived Therapeutic Vaccine [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of an RNActive-derived therapeutic vaccine for castration-resistant prostate cancer was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• RNActive-Derived Therapeutic Vaccine

Snippet

Sponsor: University of Florida | Conditions: Hormone Refractory Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-03-30